Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA 2021 |
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
gptkb:Rybrevant
|
| gptkbp:CASNumber |
2228321-54-9
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amivantamab
|
| gptkbp:indication |
NSCLC with EGFR exon 20 insertion mutations
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
fully human bispecific antibody
|
| gptkbp:mechanismOfAction |
EGFR and MET receptor antagonist
|
| gptkbp:pharmacokinetics |
half-life ~11 days
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
edema
rash infusion-related reactions paronychia |
| gptkbp:target |
gptkb:EGFR
gptkb:MET |
| gptkbp:UNII |
1XU1F7R2J3
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|